Experience
AstraZeneca AB
Aurobindo Pharma, Ltd.
The U.S. District Court for the District of Delaware ruled in favor of Finnegan client AstraZeneca AB, finding that the listed patent for the active ingredient, saxagliptin, in AstraZeneca’s type II diabetes drugs Onglyza® and Kombiglyze® was valid and infringed. Having conceded infringement prior to trial, 11 generic pharmaceutical companies alleged that claims directed to the compound saxagliptin were invalid as obvious. Finding that the generic defendants failed to establish by clear and convincing evidence that the asserted claims would have been obvious at the time the patent application was filed, the presiding judge held that defendants’ alleged motivations were “at odds with the teachings of the prior art” and appeared to be “the product of a classic hindsight analysis.” The generic defendants are enjoined from making, using, offering for sale, selling, or importing into the United States their proposed generic saxagliptin products before the expiration of AstraZeneca’s patent. The patent at issue was also sustained in a parallel IPR proceeding.
AstraZeneca AB v. Aurobindo Pharma, Ltd., 1:14-cv-00664, D. Del., Judge Sleet
Mylan Pharmaceuticals Inc.; Wockhardt Bio AG; Teva Pharmaceuticals USA, Inc.; Aurobindo Pharma U.S.A. Inc.; Sun Pharmaceutical Industries, Ltd.; Sun Pharma Global FZE; Amneal Pharmaceuticals, LLC v. AstraZeneca AB, IPR2015-01340, PTAB, Judges Elluru, Paulraj, Tierney
District court ruling maintains patent protection for Allergan’s Saphris®
Allergan/Forest Laboratories
The Hillman Group, Inc. v. KeyMe, LLC
The Hillman Group, Inc.
Zimmer, Inc.
AstraZeneca AB v. Lannett Holdings, Inc.
AstraZeneca AB
Bausch + Lomb; Mitsubishi Tanabe; Ube; Senju
Senju Pharmaceutical Co.; Bausch + Lomb v. Lupin Ltd.
Senju Pharmaceutical Co.; Bausch + Lomb
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.